Table 2:
Incidence of Treatment-Related Adverse Events when combining AT with immunotherapy.
| Trial ID | Phase | Immunotherapy | Anti-angiogenic therapy | Disease | Toxicity | Adverse events64–67 |
|---|---|---|---|---|---|---|
| NCT02366143 | III | Atezolizumab | Bevacizumab | NSCLC | Combined Grade≥3 58.5% Bevacizumab Grade≥3 50% |
Hematological 41.8% Hypertension 6.4% Hematological 35.7% Hypertension 6.3% |
| NCT0308304 | Ia/Ib | Anti-PD1 antibody | Apatinib | HCC、EC/EGJC | Ia Grade 3 26.7% Ib Grade3 60.6% |
Biochemistry 6.97% Hypertension 20% Hypertension 15.2% Liver function 15.2% |
| NCT02853331 | III | Pembrolizumab | Axitinib/ sunitinib | Advanced RCC | Avelumab plus Axitinib Grade≥3 75.8% Sunitinib Grade≥3 70.6% |
Liver function 20.3% Hypertension 22.1% Diarrhea 9.1% Liver function 5.5% Hypertension 19.3% Fatigue 6.6% Hematological 29.4% |
| NCT02684006 | Ib | Avelumab | Axitinib/ sunitinib | Advanced RCC | Pembrolizumab–Axitinib Grade≥3 71.2% Sunitinib Grade≥3 71.5% |
Diarrhea 6.7% Hypertension 19.3% Liver function 9.9% Hypertension 17.1% Liver function 5.7% Hematological 33.1% |
NSCLC, non-small cell lung cancer; EC, esophageal cancer; EGJC, esophageal-gastric junction cancer; RCC, renal cell carcinoma.